Determination of D- dimer level in sickle cell anemia patients under hydroxyurea treatment in Sinnar state, Sudan

Abdalrahman Fadelmula Ensaf; H.A. Abdalla Mahdi

doi:10.30574/gscbps.2020.10.2.0037

Authors

Abdalrahman Fadelmula Ensaf Alneelain University, Faculty of Medical Laboratory Sciences, Department of Hematology, Khartoum, Sudan.
H.A. Abdalla Mahdi Alneelain University, Faculty of Medical Laboratory Sciences, Department of Hematology, Khartoum, Sudan.

DOI:

https://doi.org/10.30574/gscbps.2020.10.2.0037

Keywords:

SCD, Hydroxyurea, SCA, Treatment, D-dimer

Abstract

Sickle cell disease (SCD) is a group of blood disorders typically inherited from a person's parents. The most common type is known as sickle cell anemia (SCA), is hemoglobin disorders that increase the rate of morbidity and mortality. Aim of this study is to evaluate D- dimer level in patients with sickle cell anemia (SCA) under hydroxyurea (HU) treatment. A total of 90 subjects, Homozygous (SCD) patients (HbSS) treated with Hydroxyurea (HU) (n=30), homozygous (SCD) untreated with hydroxyurea (n=30) and healthy (Hb AA) controls (n=30) matched for age (4 - 20) years, gender and socioeconomic status were enrolled from sinnar pediatric hospital. Venous blood samples 1.8 ml were collected in Trisodium citrate, centrifuged at room temperature then plasma was separated. The effect of the SCD patient's treatment with hydroxyurea on D- dimer level was investigated using Snibe MAGLUMI fully-autochemiluminescence immunoassay (CLIA) analyzer. The results of D-dimer are significantly lower (0.93±0.52ng/ml) (p value 0.000) in (SCD) under (HU) and normal control (0.39±0.14) compared to (SCD) patients without (HU) treatment (4.61±1.76ng/ml). Also, according to clinical status, SCD under HU Treatment about 73% are steady, and crises which about 27 %, SCD without HU treatment steady about 20% and crises about 80%. This reflect the significant role of HU therapy in the beneficial clinical effect. In conclusion, our study revealed low D-dimer levels and improves clinical and hematological characteristic among (SCD) patients under hydroxyurea treatment comparing with (SCD) patient without hydroxyurea treatment, while age showed no effect on the D-dimer levels.

Metrics

Metrics Loading ...

References

Stuart MJ and Nagel RL. (2004). Sickle cell disease. Lancet, 364, 1343–60.

Ahmed AAE, Maha I, Tarig OK et al. (2015). Red cell alloimmunization in blood transfusion dependent Patients with Sickle Cell Disease in El-Obied city, Sudan. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), 14(12), 137.

Ataga KI and Orringer EP. (2003). Hypercoagulability in sickle cell disease: a curious paradox. Am J Med, 115(9), 721–8.

Tomer A et al. (2001). Thrombogenesis in sickle cell disease. J Lab Clin Med, 137(6), 398–407.

Archibald RG. (1962). Acase of sickle cell anemiain sudan.Trancs R Soc Trop Med Hyg, 19(7), 389-393.

Noubouossie D, Key NS and Ataga KI. (2016). Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev, 30(4), 245–256.

Francis RB Jr. (1989). Elevated Fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis, 19(2), 105–111

Freyburger G, TrillaudH, Labrouche S.et al. (1998). D.dimer strategy in thrombosis, 79, 3237.

Babker AM. (2019). The role of Inherited Blood Coagulation Disorders in Recurrent Miscarriage Syndrome. Journal of Critical Reviews, 7(1).

Trompeter S and Robertsl. (2009). Haemoglobin F modulation in childhood sickle cell disease.,Br J Haematol, 144(3), 308 – 316.

Ali, Nada Mohammed Ahmed, et al. (2016). "Alterations in D-Dimer, Prothrombin Time and Activated Partial Thromboplastin Time as Thrombogenesis Activity Markers in Patients with Acute Myocardial Infarction." Open Journal of Blood Diseases, 6(1), 1-5.

Ataga KI and Key NS. (2007). Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program, 91–96.

Francis RB. (1991). Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagu Fibrinolysis, 2, 341–353.

Ahmed FE, Gaboli HO and Salih KMA. (2014). Clinicalprofile of sickle cell anemia in sudanese children, NMJ, 3(14), 12-19.

Sabahelzain MM and Hamamy H. (2014). The ethnic distribution of sickle cell disease in sudan.Pan Afr Med J, 2(2), 20-32.

Daak AA, Esamani E, Ali EH, Mohammed FA et al. (2016). Sickle cell disease in western sudan:genatic epidemiology and practices. Trop Med Int Health, 5(21), 642-653.

Ahmed HA and Baker EA. (1986). Sickling in the East sudan. Afr Med J, 63(6), 395-399.

Foy H, Kondi A et al. (1954).The variability of sickle cell rates in the tribes of Kenya and Southern sudan .Br Med J, 2(6), 1294-1297.

Eldour, Ahmed Abdalla Agab, et al. (2016). "Original Research Article Frequency of Rh D, C, c, E, e and Kell1 Antigens among Sudanese Patients with Sickle Cell Disease: A prospective Study from Khartoum, Sudan. Sch. J. App. Med. Sci, 4(1A), 1-5.

Francis RB. (1991) Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagu Fibrinolysis, 2, 341–353.

Hankins J and Aygun B. (2009). Pharmacoltherary in sicke cell disease: State of the art and future prospects.,Br JHaematol, 145(3), 296-308.

Tomer A, Harker LA, Kasey S and Eckman JR. (2001). Thrombogenesis in sickle cell disease. J Lab Clin Med, 137, 398–407.

Lee SP, Ataga KI, Orringer EP and Parise LV. (2006). Biologically active CD40 ligand is elevated in sickle cell disease: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc, 26, 1626–1631.

Tomer A, Harker LA, Kasey S and Eckman JR. (2001). Thrombogenesis in sickle cell disease. J Lab Clin Med, 137, 398–407.

Blood Rev. (2016). Author manuscript; available in PMC 2017 Jul 1. Published in final edited form as: Blood Rev, 30(4), 245–256.

Samir k ballas, Franca B Barton and Duane R Bonds. (2006). Hydroxyurea and sickle cell anemia: effect on quality of life, 59.

Ballas, Samir K, et al. (2006). "Hydroxyurea and sickle cell anemia: effect on quality of life." Health and Quality of Life Outcomes, 4(1), 59.

Liesner R, Mackie I, Cookson J, McDonald S, Chitolie A, Donohoe S, et al. (1998). Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol, 103, 1037–44.

Mustafa ME, Mansoor MM, Mohammed A, Babker AA. (2015). Evaluation of platelets count and coagulation parameters among patients with liver disease. World Journal of Pharmaceutical Research, 4(10), 360-8.